[Translation] A single-center, randomized, double-blind, similar product parallel control phase II clinical trial to evaluate the safety and immunogenicity of the recombinant mumps live attenuated vaccine (F genotype) in healthy subjects aged 6-59 years in China
评价基因重组腮腺炎减毒活疫苗(F 基因型)在中国6-59周岁健康受试者中的安全性和免疫原性,同时初步确定最佳免疫剂量,为Ⅲ期临床试验设计提供依据。
[Translation] To evaluate the safety and immunogenicity of the recombinant live attenuated mumps vaccine (F genotype) in healthy Chinese subjects aged 6-59 years, and to preliminarily determine the optimal immune dose to provide a basis for the design of Phase III clinical trials.